Investigator-initiated clinical studies to be launched following confirmation of tumor ...
E7820, Eisai's targeted protein degrader, showed tumor shrinkage in 38.1% of PDX models, particularly 58.3% in bile duct and 55.6% in uterine cancers. Whole-exome sequencing identified HRR gene mutations as predictive biomarkers. An investigator-initiated clinical study will evaluate E7820's safety and efficacy in Japanese patients with solid tumors.
Reference News
Investigator-initiated clinical studies to be launched following confirmation of tumor ...
E7820, Eisai's targeted protein degrader, showed tumor shrinkage in 38.1% of PDX models, particularly 58.3% in bile duct and 55.6% in uterine cancers. Whole-exome sequencing identified HRR gene mutations as predictive biomarkers. An investigator-initiated clinical study will evaluate E7820's safety and efficacy in Japanese patients with solid tumors.